neuropathy semaglutide Recurrent Idiopathic Intracranial Hypertension–Related Papilledema After Abrupt Discontinuation of Semaglutide: JNO Article: https://bit.ly/JNO_recurr_IIH_GLP1RA #brain #eye #vision #research #Neurology #NeuroOphth #Ophthalmology #Medicine #Papilledema VA Clinicians Should Counsel Semaglutide

Ongoing Monitoring Post-Approval: After approval, the FDA continues to monitor the drug through post-market surveillance

Millions of Americans are already injecting unapproved chemicals like peptides promoted by a hodgepodge of wellness influencers and celebrity podcasters

A positive recommendation followed by FDA rulemaking would create a legal 503A compounding pathway for the seven peptides under review (BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, Epitalon)

For many, this is enough to control symptoms, but not always

Phase 2 data published in 2023 demonstrated average weight loss of 24.2% at the highest dose, surpassing both Tirzepatide and Semaglutide